Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell Line
August 29, 2019 - Time: 11:00 AM Eastern Daylight Time. Duration 1 Hour
Competition is strong, fund raising strategies require value creation at each milestone. These are some of the reasons why being fast and efficient at preclinical stage is critical when developing a new monoclonal antibody as a drug. Choosing the right host cell line and isolating the right single clone able to deliver the highest titer, are some of the key activities at early stage which drug makers must focus on. If the CHO Cell line is the Gold standard for monoclonal antibodies manufacturing, all varieties of currently proposed CHO Cell lines derive from the historical CHO K1, isolated in 1957 by Theodore T. Puck at the Boston Cancer Research Foundation. In the past, some genetic improvements have delivered advantages related to cell density, productivity, long term viability, stability, and so on.